title: Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies.
abstract: Along with rising numbers of patients with metabolic syndrome, the prevalence of nonalcoholic fatty liver disease (NAFLD) has increased in proportion with the obesity epidemic. While there are no established treatments for NAFLD, current research is targeting new molecular mechanisms that underlie NAFLD and associated metabolic disorders. This review discusses some of these emerging molecular mechanisms and their therapeutic implications for the treatment of NAFLD. The basic research that has identified potential molecular targets for pharmacotherapy will be outlined.
authors.forename: Yue Ye
authors.initials: YY
authors.lastname: Huang
authors.forename: Aaron M
authors.initials: AM
authors.lastname: Gusdon
authors.affiliation: Department of Endocrinology and Metabolism, Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China. qushencn@hotmail.com.
authors.forename: Shen
authors.initials: S
authors.lastname: Qu
mesh_terms: D003474:Curcumin / Q000627:therapeutic use; D054890:Fatty Acid Synthase, Type I / Q000235:genetics / Q000378:metabolism; D005234:Fatty Liver / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D058607:Fibric Acids / Q000627:therapeutic use; D000071161:Forkhead Box Protein O1; D051858:Forkhead Transcription Factors / Q000235:genetics / Q000378:metabolism; D005786:Gene Expression Regulation; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D065626:Non-alcoholic Fatty Liver Disease; D047495:PPAR gamma / Q000235:genetics / Q000378:metabolism; D020675:Peroxisomes / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D000077297:Pregnane X Receptor; D020011:Protective Agents / Q000627:therapeutic use*; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics / Q000378:metabolism; D011987:Receptors, Steroid / Q000235:genetics / Q000378:metabolism; D045162:Thiazolidinediones / Q000627:therapeutic use; D000099150:Receptor, Farnesoid X-Activated
chemical_list: D003474:Curcumin; D054890:Fatty Acid Synthase, Type I; D058607:Fibric Acids; D000071161:Forkhead Box Protein O1; D051858:Forkhead Transcription Factors; D047495:PPAR gamma; D000077297:Pregnane X Receptor; D020011:Protective Agents; D018160:Receptors, Cytoplasmic and Nuclear; D011987:Receptors, Steroid; D045162:Thiazolidinediones; D000099150:Receptor, Farnesoid X-Activated; C085126:FOXO1 protein, human; C518729:FASN protein, human